First we assessed the ability of the different leukocidins to permeabilise bovine neutrophils.
We also assessed the ability of BAY 2402234 to induce AML differentiation in vivo.
SEM also assessed the ability of the model to fit the observed data.
We also assessed the ability of synj overexpression to rescue defective locomotor response in mnb1 (ref. 14).
We further assessed the ability of the SA129, SA138, and SA157* to antagonize the activation of ELR+ CXC chemokine receptors.
We also assessed the ability of RvD2 and MaR1 to accelerate resolution of established peritonitis (Supplementary Figure 2a, b).
We assessed the ability of CIN4 to stratify outcome in an independent cohort of patients diagnosed between 1999 and 2002.
We assessed the ability of these collaborative processes to address social and environmental goals.
We assessed the ability of fibrin sealant to facilitate tubeless management after uncomplicated percutaneous nephrolithotomy (PCNL).
To identify the Cav3.2 molecular determinants of calnexin interactions, we assessed the ability of different intracellular regions of hCav3.2 to interact with calnexin C-tail.
We assessed the ability of the mTOR inhibitor rapamycin to restore autophagy in TNFα-treated cells by performing GFP-LC3 transfections in EpoCD34/HSPCs.
